A clinical research study for Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
Summary
A clinical research study to evaluating the safety and effectiveness of an
investigational drug (Mitapivat) in study participants with Transfusion-Dependent
Alpha- or Beta-Thalassemia (ENERGIZE-T)
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 100
Inclusion criteria:
You may be eligible to participate in this trial if you are:
- ≥18 years of age
- have been diagnosed with thalassemia
Doctors will also evaluate other criteria to make sure you qualify for the study.
Exclusion criteria:
You may not be eligible to participate in this trial if you:
- have received gene therapy or bone marrow or stem cell transplantation
- female who is breast feeding or pregnant
Doctors will also evaluate other criteria to make sure you qualify for the study.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Please contact study physician Natalia Rydz at nrydz@ucalgary.ca or 403-944-3265 if you would like to learn more about this trial.
Principal investigator:
Natalia Rydz
Clinical trial:
Yes
REB-ID:
REB21-0766